As cancer drug prices approach $100,000, manufacturers are facing strong resistance from manufacturers. Now Wall Street is starting to worry.
By Kate Rawson
It’s finally starting to happen: about 18 months after the Medicare program radically changed its formula for paying for oncology...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.
The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.
The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.
Clarity on payer responses to controversial vaccine recommendations from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices may be coming.
The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
Clarity on payer responses to controversial vaccine recommendations from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices may be coming.
